

# DCE-MRI for assessment of effects of anti-angiogenic therapy: Comparison of the transfer constant (K<sub>trans</sub>) to blood permeability derived by a distributed parameter model.

C. H. Thng<sup>1</sup>, T. S. Koh<sup>2</sup>, S. Hartono<sup>1,2</sup>, H. Rumpel<sup>3</sup>, J. B. Khoo<sup>1</sup>, A. S. Low<sup>3</sup>, A. B. Ong<sup>4</sup>, N. Sukri<sup>4</sup>, B. C. Tai<sup>5</sup>, R. Soo<sup>4</sup>, R. A. Humerickhouse<sup>6</sup>, and B. C. Goh<sup>4</sup>

<sup>1</sup>National Cancer Centre, Singapore, Singapore, <sup>2</sup>Nanyang Technological University, Singapore, <sup>3</sup>Singapore General Hospital, Singapore, <sup>4</sup>National University Hospital, Singapore, <sup>5</sup>National University of Singapore, Singapore, <sup>6</sup>Abbott Laboratories, North Chicago, IL, United States

## Introduction

Dynamic contrast enhanced MRI (DCE-MRI) with tracer kinetic modeling has been proposed as a biomarker of angiogenesis imaging. Generalized kinetic (GK) model (1) and uptake integral approach (2) are commonly used DCE-MRI models whose representative parameters are K<sub>trans</sub> (1) and initial area under the signal-time curve (IAUC) (2), respectively. The distributed parameter (DP) model (3) is a DCE-MRI model that enables derivation of blood flow and capillary permeability-surface area product (PS) independently. We aim to study the DP model as an alternative method of angiogenesis assessment and correlate the above parameters to drug exposure and patient outcome in a Phase I anti-angiogenic trial.

## Materials and methods

### Patient

Twenty evaluable patients from an on-going phase I trial (ABT 869) with 3 dose escalations formed the study population. Pharmacokinetic study was performed on Day 1. Area under the concentration time curve extrapolated to infinity (AUC<sub>inf</sub>) was used as an indicator of drug exposure. Patients demonstrating progressive disease in first 2 evaluation scans (cycle 2 or 4) based on RECIST criteria were considered progressors and all other patients non-progressors.

### DCE-MRI

MRI was performed on a 1.5 Tesla scanner (Avanto, Siemens, Erlangen) using integrated surface coils (TIM, Siemens, Erlangen). A three-dimensional, fast low-angle shot (3D FLASH) sequence was used to acquire sequential images with the following parameters: repetition time TR=3.15 ms, echo time TE=1 ms, field of view (FOV) 40cm×40cm, 256×256 matrix, 10 slices with slice thickness 8mm, and temporal resolution 4 sec. To estimate native (pre-contrast) tissue T<sub>1</sub> values using the dual-flip angle method, 5 sets of pre-contrast images were acquired with the above parameters for each of two flip angles,  $\alpha = 6^\circ$  and  $10^\circ$ . This is followed by a dynamic sequence which includes 90 consecutive sets of images acquired with the above parameters and a flip angle  $\alpha = 10^\circ$ . Intravenous Gd-DTPA (Magnevist®, Bayer Schering Pharma, Berlin, Germany) at 0.2mmol/kg was injected after the 10<sup>th</sup> set of dynamic images at 3 ml/sec followed by a 20 ml saline flush at the same rate..

### Data processing & statistical analysis

Post-processing was performed off-line on a Pentium IV personal computer with Matlab™ (MathWorks, Natick, MA). Region-of-interests (ROIs) consisting of the tumor were manually identified. ROI over aorta was used as arterial input function. Percentage change in DP\_PS, K<sub>trans</sub>, and IAUC from BL in D3 and D15 were compared with the patient response. Receiver operating characteristic (ROC) curve analysis was performed using SPSS 15.0 (SPSS Inc., Chicago, IL). Correlation with AUC<sub>inf</sub> was done using Medcalc (Medcalc Software, Mariakerke, Belgium).

## Results

### Correlation with drug exposure (AUC<sub>inf</sub>)

There is good correlation between DP\_PS and AUC<sub>inf</sub> (Spearman's coefficient -0.557,  $p = 0.015$ ). Although stronger correlation is found with IAUC (Spearman's coefficient -0.683,  $p = 0.003$ ), the difference is not significant ( $p = 0.548$ ). There is no correlation for K<sub>trans</sub> (Spearman's coefficient -0.128,  $p = 0.577$ ).

### ROC analysis for predictor & non-progressor


ROC area for DP\_PS is higher than that of K<sub>trans</sub> (0.868 versus 0.429,  $p < 0.001$ ). IAUC showed a lower area compared to DP\_PS (0.692 versus 0.868) but the difference is not significant ( $p = 0.156$ ). Using a 27.4% drop from baseline to predict non-progressors, the sensitivity of DP\_PS is 69.23% and the specificity is 100% whereas sensitivity of K<sub>trans</sub> is 38.5%, and specificity 42.86%. In 8 out of 20 cases (40%), DP\_PS correctly predicted the eventual outcome whereas K<sub>trans</sub> gave the wrong prediction.

## Conclusion

Permeability-surface area product (PS) derived from distributed parameter model shows better correlation with drug exposure and may predict patient outcome better than K<sub>trans</sub>. It also performs reasonably well compared to IAUC, a parameter with heuristic approach.

## References

1. Tofts PS, et al. JMRI 1999;10:223-232.
2. Evelhoch J. JMRI 1999;10:254-259.
3. Koh TS, et al. IEEE Trans Biomed Eng 2003;50:159-167.



Example where PS predicted the outcome correctly and K<sub>trans</sub> predicted wrongly